good Thanks, and Mike, everyone. morning,
clinical involves has been DNA in boosting antigen, with immune chronic to NUC Mike As therapy. of ongoing B system. DNA the care HBV In and developing imdusiran when given patients surface with date, a trials to standard and to shown reduce our mentioned, and for our conducted approach surface reduce suppressing HBV both without untreated antigen cure functional reducing patients hepatitis
of patients reawakening imdusiran. T-cell evidence with HBV-specific addition, in been some has treatment In observed undergoing
immunomodulatory our combination designed system, approaches, checkpoint inhibitor IIa a trial PD-LX a Phase targeting the interferon, in axis. or imdusiran therapeutic evaluate vaccine, X the we X boost PD-X and To of to immune further with
in X combination AB-XXX-XXX clinical respectively. with Our evaluating and IIa with are combination vaccine, interferon imdusiran a AB-XXX-XXX, therapeutic Phase in ongoing trials, and
As data Mike track end-of-treatment at trials IIa in Congress June. these Phase of the EASL are on said, to both report
trial addition Note combination. the that PD-X inhibitor AB-XXX-XXX the of the VTP-XXX evaluate we antibody also the checkpoint and to amended nivolumab to imdusiran
expect that We this cohort of from data the end-of-treatment preliminary second half in year.
IIa third imdusiran monoclonal we Today, in combination evaluating antibody. patient we Phase have is anti-PD-LX announced trial, which that AB-XXX-XXX, screening durvalumab, initiated with an in our clinical
evaluate modulator use combination checkpoint will proprietary III While inhibitor, AB-XXX-XXX responses. PD-LX with small checkpoint trial to This with with intended boost we inhibition imdusiran, all Phase combine HBV-specific trial our oral the is specifically how trials imdusiran can are upcoming in aB-XXX. combinations of with towards these immune right molecule to finding to the inform geared immune durvalumab
evaluating discontinue is X with NUC patients that separate design. anti-PD-LX chronic suppressed Phase ongoing will XX prespecified imdusiran milligrams during trial at antibody NUC imdusiran with additional followed to imdusiran with of doses for We eligibility With times I'd to backdrop, intend the B. completion by all differ therapy receive to every for of After their be of antiviral All XX an patients into durvalumab, in open-label, immunologic patients an IIa safety, for approved receive AB-XXX-XXX the therapy will and X hepatitis NUC ongoing in assessed weeks, combination treatment, like clinical AB-XXX-XXX enroll an cohorts. XX more activity monoclonal durvalumab will therapy HBV-specific trial treatment in to will will that weeks X and be multisensor XX weeks. patients virologically and tolerability, provide information the XX period regarding cohort. of
this to timing changes antigen treatment. in checkpoint The surface explore reduction and the during trial optimal trial in of ongoing for inhibitor endpoints during safety dosing us includes treatment clinical context imdusiran and the from allows This period. the follow-up of surface antigen baseline
from small-molecule oral as our to checkpoint ways antibodies such on moving in nivolumab monoclonal differentiated the Now, our testing. that based following is AB-XXX, and on durvalumab inhibitor, preclinical proprietary
and traffics monoclonal adverse meaning chance First, systemic with liver-to-plasma events it a exposure preferentially ratio, and thus immune-related high to of liver-centric, antibodies. the the seen liver has is reducing AB-XXX minimizing
AB-XXX pharmacokinetics or quickly dosing intervals any stop potential to effects therefore, the mitigate thus dose modify for concerns. shorter has than to long-acting a of antibodies, to and, safety Second, to maximize much or effect typical dosing small-molecule allowing duration the
within a through of potential [indiscernible] our of is drug that about no AB-XXX novel effect designed to ways of are is the and known cells, double-blind, clinical of and and currently mechanism surface hours. therapy, the is acts we of reasons randomized, where dimerization within antibody internalization are in Phase investigate safety, the PD-LX HBV tolerability, receptor maintained as causing is for full from on unlike PD-LX cell which pharmacokinetics these AB-XXX AB-XXX to to of of It excited program, action days, the and AB-XXX. occupancy reconstitution Third, a binds on PD-LX the the the for of with it. Ia/Ib surface function placebo-controlled duration differentiated PD-LX evaluating in PD of trial AB-XXX-XXX. clinical results weeks pharmacodynamics antibodies. restoration by advancing reverse AB-XXX This trial, and degradation in It followed protein,
subjects X the subjects consists have Part cohort, chronic multiple receptor Part and multiple with evidence a with in generally XX dose-dependent of a And which ascending sequential each of showed AB-XXX X each subjects single date. from placebo. is ascending of up increased safety, of X subsequent levels the X in doses starting X, healthy of portion and single with review parts, to that and in trial healthy culminating cohort subjects In X PD PK cohorts AB-XXX The and tolerated we AB-XXX The data to data, HBV. is received patients doses X enrolled occupancy. dose milligrams. well Within were received with after dose trial,
of all be that occupancy of receptor samples evidence excluded the its for evaluable showed cohort, the In analyzed. from of receptor occupancy target. have PD-LX X was XX% One in samples subjects and cohort AB-XXX and indicating subjects that is XXX%, this had intended their as PD these the between X XX-milligram were with test subject interacting evaluation X cannot
We of cohorts where are X subjects of AB-XXX. Part of are trial, healthy ascending this multiple doses now receiving in
in We plays dose T-cell healthy and to could year. is this a preliminary announcing checkpoint move chronic goal B. activation, from in into X, inhibitor, of addition ascending HBV-specific pathway subjects of immune Our patients responses. possible HBV-specific immune multiple the potentially believe the this will an of the with as the imdusiran, trial, anticipate and immune enhance in that enroll Part important hepatitis We X, half role with tolerance further second combination in checkpoint data in as Part portion quickly which
With Dave financial update. Dave? turn Hastings brief that, I'll a for the over to call
